PEX9 Antibody

What is PEX19 and what is its primary function in cells?

PEX19 (Peroxisomal biogenesis factor 19) is a 33 kDa protein that plays dual essential roles in peroxisomal biogenesis. It functions both as a cytosolic chaperone and as an import receptor for peroxisomal membrane proteins (PMPs). In its chaperone role, PEX19 binds and stabilizes newly synthesized PMPs in the cytoplasm by interacting with their hydrophobic membrane-spanning domains. As an import receptor, it targets these PMPs to the peroxisome membrane through binding to the integral membrane protein PEX3. Through these interactions, PEX19 ensures the functional integrity of peroxisomes, which are crucial for metabolic processes including fatty acid beta-oxidation and detoxification of hydrogen peroxide .

Additionally, PEX19 has been found to exclude CDKN2A from the nucleus and prevent its interaction with MDM2, which results in active degradation of TP53, indicating potential roles beyond peroxisome biogenesis .

What types of PEX19 antibodies are available for research, and how do they differ?

Several types of PEX19 antibodies are available for research applications, primarily:

• Rabbit Polyclonal Antibodies: These recognize multiple epitopes of PEX19 and are suitable for various applications including Western blot (WB), immunohistochemistry on paraffin sections (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF). They typically react with human samples and are generated against recombinant fragment proteins within human PEX19 .

• Rabbit Recombinant Monoclonal Antibodies: These offer greater specificity and reproducibility compared to polyclonal antibodies. They are suitable for immunoprecipitation (IP), Western blot (WB), immunocytochemistry/immunofluorescence (ICC/IF), and intracellular flow cytometry. These have been validated with human and rat samples and are often cited in peer-reviewed publications .

The key differences lie in specificity, reproducibility between lots, and application versatility. Monoclonal antibodies provide more consistent results across experiments but may recognize fewer epitopes than polyclonal antibodies.

What are the standard methods for validating PEX19 antibody specificity before experimental use?

Validating PEX19 antibody specificity involves several critical steps:

• Western Blot Validation: Verify if the antibody detects bands at the expected molecular weight (33 kDa for PEX19). Note that in some experimental contexts, observed band sizes of 35 kDa and 40 kDa have been reported, likely representing post-translationally modified forms .

• Positive Control Tissues/Cells: Use cell lines known to express PEX19, such as MOLT4 (human lymphoblastic leukemia T lymphoblast) or A549 (human lung carcinoma epithelial cells) .

• Negative Controls: Include secondary antibody-only controls to confirm specific binding. Additionally, use non-expressing tissues or knockdown/knockout samples where PEX19 expression is reduced or absent.

• Cross-reactivity Testing: For antibodies claimed to work across species, test samples from each relevant species to confirm cross-reactivity.

• Epitope Mapping: Understanding precisely which region of PEX19 the antibody recognizes can help predict potential cross-reactivity and explain unexpected results in certain experimental contexts .

How should researchers optimize PEX19 antibody dilutions for different applications?

Optimization of PEX19 antibody dilutions is application-specific and requires methodical testing:

For each application, begin with the manufacturer's recommended dilutions then perform a dilution series to determine optimal concentration that maximizes specific signal while minimizing background. Document the exact conditions that produce optimal results (including buffer compositions, incubation times and temperatures) to ensure reproducibility .

What experimental controls are essential when working with PEX19 antibodies?

Essential controls for PEX19 antibody experiments include:

• Positive Tissue/Cell Controls: Include samples known to express PEX19, such as MOLT4 or HeLa cells. Western blots using these samples should detect bands at the expected molecular weight (33 kDa and potentially 35/40 kDa) .

• Isotype Controls: For immunofluorescence and flow cytometry, include isotype-matched irrelevant antibodies (e.g., rabbit monoclonal IgG isotype control) at the same concentration as the primary antibody to assess non-specific binding .

• Secondary Antibody-Only Controls: Omit primary antibody but include secondary antibody to detect non-specific binding of the secondary antibody.

• PEX19 Knockdown/Knockout Controls: Where possible, include samples where PEX19 expression has been reduced or eliminated to confirm specificity.

• Peptide Competition Assays: Pre-incubate the antibody with the immunizing peptide to block specific binding sites as a specificity control.

• Cross-reaction Controls: If performing multi-color immunofluorescence, include single-staining controls to detect any cross-reactivity between antibodies or fluorophores .

How does epitope accessibility affect PEX19 antibody performance across different techniques?

Epitope accessibility is a critical determinant of PEX19 antibody performance:

• Subcellular Localization Effects: PEX19 exists both in cytosolic and membrane-associated pools. Antibodies recognizing different epitopes may preferentially detect one pool over the other, particularly in fixed-cell applications.

• Fixation-Dependent Effects:

  • Aldehyde fixatives (paraformaldehyde) preserve protein structure but can mask epitopes through cross-linking

  • Alcohol fixatives (methanol/ethanol) extract lipids and can alter protein conformation

  • For PEX19, 4% paraformaldehyde fixation with subsequent permeabilization using 0.1% Triton X-100 has been validated for immunofluorescence applications

• Denaturation Effects: Antibodies raised against linear epitopes perform better in applications with denatured proteins (Western blot) but may fail in applications using native proteins (immunoprecipitation). Conversely, antibodies recognizing conformational epitopes may have opposite performance characteristics.

• Protein Interaction Masking: PEX19's interactions with multiple peroxisomal membrane proteins may physically mask certain epitopes. This is particularly relevant for co-immunoprecipitation experiments where the antibody binding site might overlap with protein interaction domains .

How can PEX19 antibodies be used to investigate the relationship between peroxisome dysfunction and neurodegenerative diseases?

PEX19 antibodies provide valuable tools for investigating peroxisome dysfunction in neurodegenerative contexts:

• Co-localization Studies: Use PEX19 antibodies in conjunction with markers of protein aggregates (e.g., tau in Alzheimer's disease) to examine potential co-localization or altered peroxisome distribution in affected tissues. Similar to anti-tau antibody approaches, targeting specific functional domains of PEX19 may provide different insights into disease mechanisms .

• Biochemical Fractionation: Employ PEX19 antibodies in subcellular fractionation experiments to quantify peroxisome abundance and integrity in normal versus diseased tissue samples.

• Proximity Ligation Assays: Combine PEX19 antibodies with antibodies against disease-associated proteins to detect potential novel interactions using techniques like proximity ligation assay (PLA).

• Post-translational Modification Analysis: Use modification-specific antibodies alongside PEX19 antibodies to assess whether disease states alter PEX19 regulation through phosphorylation, ubiquitination, or other modifications.

• In vivo Models: Apply PEX19 antibodies to tissue sections from animal models of neurodegeneration to track peroxisome changes throughout disease progression, similar to tracking approaches used with anti-tau antibodies in Alzheimer's models .

The therapeutic antibody development lessons from tau research suggest that careful epitope selection is critical - antibodies targeting different regions of proteins can have vastly different functional effects, which should inform experimental design when using PEX19 antibodies to study disease mechanisms .

What approaches can be used to develop more specific PEX19 antibodies for challenging experimental contexts?

Developing highly specific PEX19 antibodies requires advanced approaches:

• Computational Design Methods: Apply biophysics-informed modeling to predict antibody-antigen interactions and design antibodies with customized specificity profiles. This approach has been successfully used to create antibodies with either specific high affinity for particular target epitopes or cross-specificity for multiple targets .

• Phage Display Selection: Utilize phage display with a focused antibody library, particularly targeting the complementarity-determining regions (CDRs), especially CDR3 which significantly influences binding specificity. This technique allows screening of approximately 1.6 × 10^5 combinations of amino acids to identify highly specific binders .

• Epitope Mapping for Rational Design: Systematically map the binding epitopes of existing antibodies to identify regions that provide maximum specificity. Focus on unique, accessible regions of PEX19 that differ from related proteins.

• Machine Learning Approaches: Employ machine learning algorithms trained on experimental antibody binding data to predict and design novel antibody sequences with enhanced specificity profiles .

• Negative Selection Strategies: Include negative selection steps against similar proteins or specific molecular regions to remove cross-reactive antibodies from the selection pool.

These approaches reflect cutting-edge techniques for generating antibodies with custom specificity profiles, as demonstrated in research on highly specific antibody development .

How can researchers distinguish between the multiple cellular roles of PEX19 using antibody-based approaches?

Distinguishing between PEX19's different functions requires sophisticated antibody-based approaches:

• Domain-Specific Antibodies: Develop antibodies targeting distinct functional domains of PEX19:

  • N-terminal domain (involved in PMP binding)

  • C-terminal domain (involved in PEX3 interaction and membrane targeting)

  • Farnesylation site (important for membrane association)

• Proximity-Based Assays: Combine PEX19 antibodies with proximity labeling techniques (BioID, APEX) to identify different PEX19 interaction networks in various cellular compartments.

• Conditional Knockout/Mutation Studies: Use PEX19 antibodies in conjunction with domain-specific mutations or conditional knockout systems to correlate protein presence with specific functions.

• Fractionation-Based Approaches: Employ subcellular fractionation followed by immunoblotting with PEX19 antibodies to quantify the distribution between cytosolic (chaperone function) and membrane-associated (import receptor function) pools.

• Modified Protein Correlation Profiling: Combine antibody-based detection with gradient centrifugation and mass spectrometry to track PEX19-associated proteins across different cellular compartments.

• Functional Blocking Experiments: Use antibodies that specifically block certain interaction domains of PEX19 to selectively inhibit specific functions while leaving others intact.

This multi-faceted approach allows researchers to dissect the complex roles of PEX19 in peroxisome biogenesis, protein trafficking, and potentially in other cellular processes like cell cycle regulation through its interaction with CDKN2A .

How should researchers interpret unexpected PEX19 antibody band patterns in Western blots?

When encountering unexpected band patterns with PEX19 antibodies in Western blots, researchers should consider:

• Expected vs. Observed Molecular Weights:

  • Expected molecular weight for PEX19: 33 kDa

  • Commonly observed additional bands: 35 kDa and 40 kDa

• Post-translational Modifications: Higher molecular weight bands may represent:

  • Farnesylated PEX19 (~1 kDa increase)

  • Phosphorylated forms (multiple phosphorylation sites)

  • Ubiquitinated forms (significant increase in molecular weight)

• Isoform Detection: Human PEX19 has multiple transcript variants that can generate protein isoforms of different sizes.

• Sample Preparation Artifacts:

  • Insufficient denaturation: Heat samples in SDS sample buffer at 95°C for 5 minutes

  • Incomplete reduction: Ensure fresh DTT or β-mercaptoethanol in sample buffer

  • Protein degradation: Add protease inhibitors during sample preparation

• Experimental Validation Approaches:

  • Peptide competition assays to confirm specificity of unexpected bands

  • siRNA knockdown to verify which bands decrease with reduced PEX19 expression

  • Mass spectrometry analysis of excised gel bands to confirm protein identity

  • Comparison of different anti-PEX19 antibodies recognizing different epitopes

Researchers should document that doublets or additional bands with PEX19 antibodies have been reported in multiple studies and may represent biologically relevant modified forms rather than non-specific binding .

What are the most common causes of false positive/negative results with PEX19 antibodies and how can they be addressed?

Common causes of false results with PEX19 antibodies include:

When troubleshooting:

• Always include positive and negative controls

• Test multiple antibody concentrations

• Consider using alternative antibodies targeting different epitopes

• Document detailed experimental conditions to track sources of variability

For peroxisomal proteins like PEX19, particular attention should be paid to sample preparation methods that preserve the integrity of membrane-associated proteins .

How do protein-protein interactions affect PEX19 antibody binding and experimental interpretation?

PEX19's extensive protein interaction network significantly impacts antibody accessibility and experimental outcomes:

• Epitope Masking by Protein Complexes:

  • PEX19 interacts with multiple peroxisomal membrane proteins (PMPs)

  • PEX19-PEX3 interaction may block epitopes in the C-terminal region

  • Cargo PMPs bound to PEX19 may shield N-terminal epitopes

  • The CDKN2A interaction may mask epitopes in regulatory domains

• Conformation-Dependent Epitope Availability:

  • PEX19 likely undergoes conformational changes upon binding different partners

  • These conformational states may expose or conceal particular epitopes

  • Native vs. denatured conditions will affect detection of conformation-dependent epitopes

• Subcellular Localization Effects:

  • Cytosolic PEX19 (chaperone function) may present different epitope accessibility compared to membrane-associated PEX19 (receptor function)

  • Antibodies may preferentially detect one pool over the other

• Experimental Solutions:

  • Use antibody panels targeting different PEX19 epitopes

  • Employ mild detergents to preserve protein-protein interactions when needed

  • Apply cross-linking approaches to stabilize transient interactions before antibody application

  • Consider native vs. denaturing conditions based on experimental questions

• Interpretation Guidelines:

  • Negative results in co-IP experiments may reflect epitope blocking rather than absence of interaction

  • Differential staining patterns in IF may indicate functional PEX19 pools rather than antibody artifacts

  • Quantitative differences in detection across cell types may reflect different PEX19 interaction states

How can customized PEX19 antibodies be developed to investigate peroxisome-related disease mechanisms?

Developing customized PEX19 antibodies for disease research involves:

• Domain-Targeted Antibody Design: Similar to anti-tau antibody approaches in Alzheimer's research, targeting specific functional domains of PEX19 might provide different therapeutic insights. Lessons from anti-tau research suggest that antibodies targeting certain domains (like the microtubule-binding region of tau) may be more effective at preventing pathological processes than those targeting other regions .

• Computational Antibody Design: Using biophysics-informed modeling and extensive selection experiments to predict and design antibodies with desired binding profiles. This approach allows the creation of antibodies with either:

  • Specific high affinity for a particular PEX19 epitope

  • Cross-specificity for multiple epitopes or modified forms

• Conditional Binding Antibodies: Develop antibodies that selectively recognize disease-associated PEX19 conformations or modifications, similar to conformation-specific antibodies used in neurodegeneration research.

• High-Throughput Generation Methods:

  • Phage display experiments with antibody libraries based on human V domains

  • Systematic variation of complementarity determining regions (CDRs), particularly CDR3

  • Selection against multiple ligands to create antibodies with defined cross-reactivity or specificity profiles

• Validation in Disease Models: Test these custom antibodies in cellular and animal models of peroxisomal disorders to understand both diagnostic and potential therapeutic applications.

This approach combines lessons from therapeutic antibody development in neurodegenerative diseases with cutting-edge computational antibody design methods .

What novel experimental techniques are emerging for studying PEX19 dynamics and interactions using antibody-based approaches?

Emerging antibody-based techniques for studying PEX19 include:

• Single-Molecule Tracking: Combining anti-PEX19 antibody fragments with quantum dots or other bright, photostable fluorophores to track the movement and interactions of individual PEX19 molecules in living cells.

• Super-Resolution Microscopy Applications: Using highly specific PEX19 antibodies with techniques like STORM, PALM, or STED microscopy to visualize peroxisome biogenesis events at nanoscale resolution.

• Antibody-Based Proximity Sensors: Creating split fluorescent protein constructs or FRET pairs linked to anti-PEX19 antibody fragments and antibodies against interaction partners to monitor protein-protein interactions in real-time.

• Optogenetic Control with Antibody Targeting: Combining photoswitchable protein domains with anti-PEX19 antibody fragments to enable light-controlled manipulation of PEX19 function.

• Antibody-Mediated Degradation Approaches: Adapting technologies like PROTAC (Proteolysis-Targeting Chimeras) to create bifunctional molecules containing PEX19-binding antibody fragments linked to E3 ligase recruiting moieties for targeted protein degradation.

• In vivo Antibody-Based Imaging: Developing anti-PEX19 antibodies compatible with in vivo imaging techniques to study peroxisome dynamics in animal models of disease.

• Intrabodies for Organelle Manipulation: Engineering antibody fragments that can be expressed intracellularly to track, modify, or inhibit specific PEX19 functions within living cells.

These approaches represent the frontier of antibody-based techniques and can be adapted from successful applications in other fields like therapeutic antibody development .